On August 31, 2022 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, reported that members of the management team will participate in the following upcoming investor conferences (Press release, 2seventy bio, AUG 31, 2022, View Source [SID1234618802]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

17th Annual Citi BioPharma Conference, "Cell Therapy Part 1" panel on Wednesday, September 7, 2022 at 9:40am ET in Boston, MA
2022 Morgan Stanley Global Healthcare Conference, fireside chat on Wednesday, September 14, 2022 at 11:45am ET in New York, NY
Live webcasts will be available via the Investors and Media section of 2seventy bio’s website at View Source A replay will be archived on 2seventy bio’s site for 30 days following the event.

On August 31, 2022 SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, reported a regulatory update on emactuzumab, in development for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases (Press release, SynOx Therapeutics, AUG 31, 2022, View Source [SID1234618800]). The European Medicines Agency (EMA) has designated emactuzumab as an orphan medicinal product in the indication of TGCT for both localized and diffuse types of the disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TGCT is a rare, chronically debilitating disease affecting the synovium, tendon sheaths and bursa membranes, primarily of knee, hip and ankle joints. It causes loss of function of the affected joints, pain, stiffness and limited range of motion. TGCT has an incidence of 43 cases per million patient years, of which 4 per million patient years relate to diffuse TGCT1. No systemic treatments have been approved for TGCT in the EU. Most patients receive surgical intervention, with a post-surgery recurrence rate of up to 50%2.

Emactuzumab is a novel monoclonal antibody inhibiting CSF-1R that offers a short course of treatment. Phase I/II studies indicated good tolerability and a manageable safety profile and substantial preliminary efficacy in TGCT patients with rapid, robust tumour reduction and durable response.

SynOx is planning a phase III trial (TANGENT) to assess the efficacy and safety of emactuzumab in patients with localized or diffuse TGCT where surgical removal of the tumour is not viewed as an option. More details can be found on www.clinicaltrials.gov (with trial identifier NCT05417789) and at www.tangentstudy.com.

Ray Barlow, Chief Executive Officer of SynOx, said: "We have made significant progress in the development of emactuzamab in TGCT in the last 12 months. The positive opinion regarding the orphan drug designation marks an important step in SynOx’s continuing journey to provide a potential therapeutic option for patients with this debilitating disease. We are now recruiting patients on to our phase III registrational trial (TANGENT) and look forward to providing an update on progress in the near future."

On August 31, 2022 Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, reported that President and CEO Bo Rode Hansen by mutual agreement will leave his position with immediate effect (Press release, Scandion Oncology, AUG 31, 2022, View Source,c3623640 [SID1234618798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Johnny Stilou, who has been employed by Scandion as Chief Financial Officer since July 2021, has been appointed acting CEO effective immediately. The process to identify a new permanent CEO has started.

Bo Rode Hansen will also step down as a member of the Board of Directors of Scandion with immediate effect.

"I am proud of what I and the whole team have accomplished during these last two years since I joined. Scandion is a very different company today compared to when I took over as CEO. It is time for me to move on to new endeavors, and I wish all the best for Scandion in the future", says Bo Rode Hansen.

"The Board wishes Bo Rode Hansen best of luck as he pursues new opportunities. We have initiated the process to identify a new CEO for Scandion with the right qualifications and experience. The team remains focused on delivering on the operational priorities of the company", says Martin Møller, Chairman of the Board of Directors.

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 31, 2022, at 11.45 CET.

On August 30, 2022 Scottish biotech company, aTen Therapeutics, reported a £282,733 Innovate UK grant to advance a promising new therapy for breast cancer (Press release, aTen Therapeutics, AUG 30, 2022, View Source [SID1234625372]). The award will allow the company, in collaboration with scientists at ARU (Cambridge), to accelerate the development of its novel human monoclonal antibody ATN-E11.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ATN-E11 has already been shown to prolong survival in experimental models of cancer. It targets the angiotensin-II type I receptor (AT1R), which is overexpressed in a range of different cancers. This overexpression stimulates tumour growth and increases the ability of malignant cancer cells to invade and migrate. By blocking the receptor, ATN-E11 could become a powerful new cancer treatment.

Breast cancer is the most commonly diagnosed cancer globally. With an estimated 2.3 million new cases in 2020, it accounts for 1 in 4 female cancer diagnoses and 685,000 deaths annually. There are several subtypes of breast cancer with different molecular and clinical features (including drug resistance) that dictate and limit treatment options, so demand for novel therapies remains very high.

Dr Karen Spink, Head of Medicines at Innovate UK, said: ‘This exciting project, funded through our Biomedical Catalyst Programme, addresses a critical unmet need for better targeted and more effective cancer treatments. Access to a diverse armoury of precision therapies is at the heart of our mission on cancer, that promises to radically improve patient outcomes.’

aTen Therapeutics’ CEO, Ian Abercrombie, said: ‘We’re excited by the potential of our technology to extend and improve lives. The Innovate UK grant is a great endorsement of this potential and the hard work of our team in Edinburgh. We look forward to progressing ATN-E11 towards clinical trials, and ultimately providing a new treatment option for people living with breast cancer.’

Prof Chris Parris, Head of School of Life Sciences at ARU, said: ‘We’re delighted to be working with the aTen Therapeutics team to explore this exciting new approach to cancer treatment and we look forward to generating key data in the coming months. Our first target is breast cancer but the therapy could also be effective in many other cancer types.’

On August 30, 2022 Helix BioPharma Corp. (TSX: "HBP") ("Helix" or the "Company"), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, reported that it has completed the buyback of the outstanding amount of the convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, "Lind") (Press release, Helix BioPharma, AUG 30, 2022, View Source [SID1234619307]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company entered into the Agreement with Lind in May 2021 and closed the first tranche under the Agreement for gross proceeds of $3,500,000 shortly thereafter (See Press Release dated May 13 2021).

The Company has now bought back the amount outstanding of the Convertible Security under the Agreement, which is C$2,061,875.

"Paying off our convertible security paired with a robust plan to reduce overheads, operating and general and administrative expenses, gives Helix longevity to focus and execute on our strategy. We continue to be excited about our asset LDOS47 and its journey to bring new and potentially life changing therapies to patients suffering with cancers." commented Artur Gabor, CEO of Helix.